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Preliminary studies have shown that endothelial-monocyte-activating
polypeptide-II (EMAP-II) induces autophagy and inhibits the viability of glioma
cells via an unknown molecular mechanism. This study explored the possible
mechanisms associated with EMAP-II-induced autophagy in glioma cells by
regulation of the expression of microRNA-20a (miR-20a). EMAP-II effectively
inhibited the viability, migration and invasion of human U-87 and U-251 glioma
cells. EMAP-II also up-regulated the expression level of autophagy biomarker
microtubule-associated protein one light chain 3 (LC3)-II/I, autophagy related
gene ATG7 and ATG5, but down-regulated autophagy substrate P62/SQSTM1
protein expression. The expression levels of miR-20a decreased significantly after
U-87 and U-251 cells were treated with EMAP-II. MiR-20a overexpression partly
reversed the EMAP-II-induced up-regulation of LC3-II/I and down-regulation of
P62/SQSTM1. MiR-20a had a negative regulatory effect on the expression of the
proteins ATG7 and ATG5; which were also targets of miR-20a, as detected by
a dual-luciferase reporter assay. In addition, both EMAP-II and miR-20a inhibition
significantly reduced the viability, migration and invasion of U-87 and U-251 cells,
and their combination showed a synergistic effect. Furthermore, nude mice carrying
silencing-expressed miR-20a combined with EMAP-II treatment produced the
smallest tumors and the highest survival. In summary, low-dose EMAP-II increased
expression levels of ATG5 and ATG7 via down-regulation of the expression of
miR-20a. This activated the autophagy pathway, thereby significantly inhibiting the
viability, migration and invasion of U-87 and U-251 glioma cells. The combined
treatment of EMAP-II with a miR-20a inhibitor showed a synergistic effect against
glioma.
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INTRODUCTION
Glioma is regarded as the most prevalent primary malignant
intracranial neoplasm. Glioblastoma is the type of glioma
that accounts for 50–60% of malignant brain tumors
(Jakab et al., 2011). Glioblastoma has been defined as
a grade III-IV malignant tumor by the World Health
Organization due to its high degree of malignancy and
active mitosis. Existing treatments for glioblastoma include
surgery, postoperative radiotherapy, chemotherapy, and
other adjuvant therapies; however, treatment efficacy is
poor due to its high malignancy, strong invasiveness, and
resistance to radiotherapy and chemotherapy (McLendon and
Halperin, 2003; Wen and Kesari, 2008; Bartek et al., 2012).
Therefore, a novel strategy is urgently needed for glioblastoma
treatment.
Endothelial-monocyte-activating polypeptide-II (EMAP-II),
a multifunctional polypeptide, has pro-inflammatory and
antiangiogenic activities (Mogylnytska, 2015). EMAP-II has been
widely applied as a treatment because it inhibits the growth,
proliferation and metastasis of primary and metastatic tumors
(Schwarz et al., 1999). EMAP-II significantly inhibits the activity
of pancreatic ductal adenocarcinoma cells (Schwarz et al.,
2010) and exerts anti-cancer effects in prostate adenocarcinoma
xenografts (Reznikov et al., 2007). Our preliminary studies have
demonstrated that low-dose EMAP-II treatment can increase
permeability of the blood-tumor barrier (BTB; Xie et al., 2010).
These results indicate that the anti-tumor effects of EMAP-II
are mediated by opening of the BTB, which enables penetration
of anticancer drugs. Our previous findings showed that low-
dose (0.05 nM) EMAP-II directly induces apoptosis of rat
C6 glioma cells via the mitochondrial pathway (Liu et al.,
2015b); EMAP-II induces autophagy of U-118 glioma cells in
addition to inhibiting their activity (Liu et al., 2013). This
demonstrates that EMAP-II suppresses the viability of glioma
cells through apoptosis or autophagy, which leads to an anti-
tumor effect.
Autophagy is an evolutionarily conserved process that is
often activated under cellular stress (Kroemer et al., 2010).
Autophagy can protect cells from damage, but can also induce
cell death (Shen and Codogno, 2011). Studies have increasingly
observed death of tumor cells due to autophagy (Akar et al.,
2008; Seong et al., 2014). Temozolomide, a sensitive drug for
treatment of glioma, causes G2/M phase arrest in glioma cells
and induces autophagic cell death instead of apoptosis (Kanzawa
et al., 2003, 2004). We speculate that malignant glioblastoma
is more sensitive to autophagic cell death pathways (Lefranc
et al., 2005, 2006) and that EMAP-II may induce glioma cell
death through autophagy, but the molecular mechanism remains
unclear.
MicroRNA is highly involved in the regulation of various
physiological and pathological responses in cells (Bartel, 2004,
2009; Ebert and Sharp, 2012), and it can also modulate
autophagic signaling networks, most notably in cancer
(Frankel et al., 2011; Fu et al., 2012; Korkmaz et al., 2012).
MicroRNA-20a (MiR-20a), a miR-17-92 family member
located on chromosome 13, is highly expressed in glioma
tissues; overexpression of miR-20a promotes proliferation
of U-251 glioma cells, suggesting a tumor-promoting effect
(Yao et al., 2012). Furthermore, miR-20a is also considered
as an autophagy-related gene (ATG) and it may participate
in regulating leucine deprivation-induced autophagy by
changing intracellular levels of key autophagy-related proteins
in C2C12 myoblasts (Wu et al., 2012). These findings suggest
that low miR-20a expression contributes to up-regulation of
autophagy-related protein expression, activates autophagy,
and inhibits the proliferation of glioma cells. Whether
EMAP-II induces autophagy through down-regulation of
miR-20a expression, and thus affects the viability of glioma cells,
is not known.
This study aims to verify whether low-dose (0.05 nM)
EMAP-II treatment induces autophagy in U-87 and U-251
glioma cells by regulation of the expression of miR-20a, and
explores the molecular mechanisms associated with EMAP-II-
induced glioma cell autophagy.
MATERIALS AND METHODS
Cell Lines and Cell Cultures
Human malignant glioma cell line U-87, U-251 and human
embryonic kidney HEK293T cell line were purchased from
Shanghai Institutes for Biological Sciences and Cell Resource
Center (MD, USA). U-87 and HEK293T cells were cultured
in DMEM supplemented with 10% fetal bovine serum
(FBS, Life Technologies Corporation, Paisley, UK). U-251
cells were cultured in DMEM/F12 supplemented with 10%
FBS. All cells were cultured at 37◦C in an atmosphere of
5% CO2 and 95% air.
Experimental Groups
To test the effect of EMAP-II on U-87 and U-251 cells, the
experiments were divided into five groups (n = 8): (1) Control
group, cells were treated with 0.9% sodium chloride (NS);
(2) EMAP-II 0.5 h group, cells were treated with EMAP-II for
0.5 h; (3) EMAP-II 1 h group, cells were treated with EMAP-II
for 1 h; (4) EMAP-II 3 h group, cells were treated with EMAP-II
for 3 h; and (5) EMAP-II 6 h group, cells were treated with
EMAP-II for 6 h. EMAP-II (Sigma–Aldrich, St. Louis, MO, USA)
was dissolved in 0.9% sodium chloride, and 0.05 nM was selected
as the optimal concentration for our investigation according to
our previous research (Liu et al., 2013).
To investigate whether autophagy or apoptosis was involved
in the process of EMAP-II regulating glioma cells, the
autophagy inhibitor 3-Methyladenine (3-MA; Sigma–Aldrich,
St. Louis, MO, USA) or apoptosis inhibitor Z-VAD-FMK
(Z-VAD; Sigma–Aldrich, St. Louis, MO, USA) were
administered before EMAP-II. 3-MA (2 mM) and Z-VAD
(100 µm) were given 1 h prior to EMAP-II administration. Cells
were divided into eight groups (n = 8): (1) Control group, cells
were treated with 0.9% sodium chloride; (2) EMAP-II group,
cells were treated with EMAP-II for 0.5 h; (3) 3-MA group,
cells were treated with 3-MA for 1 h; (4) EMAP-II + 3-MA
group; (5) Z-VAD group, cells were treated with Z-VAD for 1 h;
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(6) EMAP-II + Z-VAD group; (7) 3-MA + Z-VAD group; (8)
EMAP-II + 3-MA + Z-VAD group.
In order to study the effect of miR-20a on EMAP-II inducing
autophagy of U-87 and U-251 glioma cells, the experiments were
divided into 10 groups (n = 8): (1) Control group; (2) EMAP–II
group; (3) miR-20a (+) NC group, transfected with negative
control of miR-20a overexpression; (4) miR-20a (+) group,
transfected with miR-20a overexpression; (5) miR-20a (−) NC
group, transfected with negative control of miR-20a silencing;
(6) miR-20a (−) group, transfected with miR-20a silencing;
(7) EMAP-II + miR-20a (+) NC group; (8) EMAP-II + miR-20a
(+) group; (9) EMAP-II + miR-20a (−) NC group; and
(10) EMAP-II + miR-20a (−) group.
To further verify the regulation effect of miR-20a on ATG7
and ATG5 expression, the experiments were divided into
five groups: (1) Control group; (2) miR-20a (+) NC group;
(3) miR-20a (+) group; (4) miR-20a (−) NC group; and
(5) miR-20a (−) group.
To study the effect of EMAP-II and miR-20a inhibitor
alone and in combination on cell proliferation, migration, and
invasion, U-87 and U-251 cells were divided into six groups
(n = 8): (1) Control group; (2) EMAP-II group; (3) miR-20a
(−) NC group; (4) miR-20a (−) group; (5) NS + miR-20a (−)
NC group, treatment with 0.9% sodium chloride after negative
control of miR-20a silencing transfection; and (6) EMAP-II +
miR-20a (−) group.
Cell Transfection
Cells were seeded on six-well plates cultured overnight,
then transfected with miR-20a mimic, miR-20a inhibitor, or
their respective negative control (GenePharma, Shanghai,
China) using lipofectamine 2000 reagent (Life Technologies
Corporation) according to the manufacturer’s instructions.
After 6 h transfection, the medium was removed and
replaced with fresh medium. The cells were harvested
after 48 h. After the cell clones of miR-20a overexpression
or silencing were established, EMAP-II was administrated
for 0.5 h.
Cell Viability Assay
Cell viability was analyzed by MTT (Solarbio Company, Beijing,
China) assay. Cells were seeded in 96-well plates at a density
of 5 × 103 cells/well. Cells were incubated overnight and
then treated with EMAP-II (0.05 nM) for 0.5, 1, 3 and 6 h,
while treatments with 0.9% sodium chloride as control. Then,
the medium was replaced with fresh medium, and the cells were
cultured at 37◦C for 24 h. Afterward, 5 mg/mL MTT medium
was added to each well and incubated for another 4 h. Then
the media were carefully removed and the formazan crystals
were solubilized by 150 µL DMSO (Sigma-Aldrich, St. Louis,
MO, USA). Afterward, the optical density (OD) values were
determined by spectrophotometry at 570 nm.
Cell Migration and Invasion Assay
Cell migration and invasion abilities were evaluated by 24-well
transwell chamber with 8 um pore size (Costar, USA). Cells were
suspended in 100 µL serum-free medium and then added to
the upper chamber (without Matrigel for cell migration assay)
or seeded on the upper chambers pre-coated with Matrigel
(for cell invasion assay), while 500 µL medium with 10% FBS
was added to the lower chamber. EMAP-II (0.05 nM) was
added to lower chamber for 0.5, 1, 3 and 6 h. Then, the
medium in lower chamber was replaced with fresh medium.
After incubation for 24 h, cells migrated or invaded to the
bottom of the membrane were fixed and then stained with 20%
Giemsa. Chambers were subjected to a microscopic inspection
and counted.
Western Blot Analysis
Protein concentration of U-87 and U-251 glioma cells was
determined by the BCA protein assay (Beyotime Institute
of Biotechnology, Jiangsu, China). Proteins (20–40 µg)
were separated by 10–12% SDS-PAGE and transferred onto
nitrocellulose membrane. The membranes were blocked by
5% non-fat milk for 2 h and then incubated overnight with
primary antibodies against microtubule-associated protein
one light chain 3 (LC3, 1:1000, Abcam, Cambridge, MA,
USA, ab63817), ATG7(1:1000, Abgent, San Diego, CA,
USA, AP1813c), ATG5 (1:1000, Proteintech, Chicago, IL,
USA, 10181-2-AP), P62/SQSTM1 (1:1000, Abcam, Cambridge,
MA, USA, ab56416), GAPDH (1:10,000, Proteintech,
Chicago, IL, USA, 6000-4-Ig), respectively. After washing
with TBST, The membranes were then incubated with
secondary antibodies. The protein bands were visualized
with enhanced chemiluminescence (ECL) kit (Santa Cruz
Biotechnology) and scanned with Chemi Imager 5500 V2.03
Software.
RNA Extraction and Quantitative RT-PCR
Total RNA was isolated using Trizol reagent (Life Technologies
Corporation, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Real-Time PCR analysis was
performed to test the expression levels of miR-20a, ATG7 and
ATG5 by means of a 7500 Fast Real-Time PCR System. For
quantification of miR-20a expression, reverse transcription
and real-time PCR amplification were carried out using
Taqman MicroRNA Reverse Transcription Kit and Taqman
Universal Master Mix II with the TaqMan MicroRNA Assay
of miR-20a and U6 (Applied Biosystems, Foster, CA, USA),
respectively. For quantification of ATG7 and ATG5 mRNA,
reverse transcription and real-time PCR amplification were
carried out using RT-PCR kit and SYBR Premix Dimer Eraser
(TaKaRa, Dalian, China) with the gene expression assays of
ATG7, ATG5 and GAPDH (Applied Biosystems), respectively.
Fold changes were calculated by relative quantification (2−44Ct)
method.
Immunofluorescence Staining
Cells were seeded onto cover slips in the six-well plates and
incubated for 24 h. Cells were stained with LysoTracker
Red at a final concentration of 50 nM. Then, cells were
fixed in 4% paraformaldehyde for 20 min, blocked with
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5% BSA for 2 h, and incubated with the primary antibody
for LC3 (1:150, Abcam, Cambridge, MA, USA, ab63817)
or P62/SQSTM1 (1:500, Abcam, Cambridge, MA, USA,
ab56416) at 4◦C overnight. After that, cells were washed
and incubated with a secondary antibody conjugated to
Alexa Fluor 488 and Alexa Fluor 555 (Beyotime Institute
of Biotechnology, Jiangsu, China). The cells were then
counterstained with DAPI (Beyotime Institute of Biotechnology,
Jiangsu, China) for 10 min and visualized with a confocal
microscope.
Reporter Vectors Constructs and
Luciferase Assays
Putative binding site between the 3′UTR of ATG7 (ATG5)
mRNA and the seed region of miR-20a were predicted by
TargetScan Human Release 6.2. HEK293 cells were seeded
into a 96-well plate and cultured overnight at 37◦C. After that,
cells were co-transfected with the wild-type or mutated ATG7
(ATG5)-3′UTR reporter plasmid (GenePharma, Shanghai,
China), and transfected with miR-20a mimic or miR-20a mimic
NC. Luciferase assays were performed 48 h later using the
Dual-Luciferase Reporter Assay System (Promega, Beijing,
China).
Tumor Xenograft Implantation in Nude Mice
The stably transfected U-87 and U-251 cells were used in
the in vivo study. Lentivirus encoding miR-20a silencing was
generated using pLenti6.3/V5eDEST Gateway Vect—or Kit (Life
Technologies Corporation, Carlsbad, CA, USA). The miR-20a
silencing was ligated into the pLenti6.3/V5eDEST vector
(GenePharma, Shanghai, China) and then pLenti6.3/V5eDEST-
miR-20a-scilecing vector was generated. Lentivirus was
generated in 293FT cells using the ViraPower Packaging Mix.
After infection, the stable expressing cells of miR-20a-silencing
[miR-20a (−)] were picked.
Four-week-old BALB/C athymic nude mice were purchased
from the Vital River Company (Beijing, China). All experiments
were carried out under the approval of the Administrative
Panel on Laboratory Animal Care of China Medical University.
The animals were free to autoclaved food and water during
the study. For subcutaneous implantation, 3 × 105 cells
were inoculated into the right upper flank regions of
the mice. Tumor volume was measured every 5 days when
the tumors were apparently seen and calculated by the formula:
volume (mm3) = length × width2/2. the mice were treated
with 80 ng/kg EMAP-II or 0.9% sodium chloride every 12 h.
For survival analysis in orthotopic inoculations, 3 × 105 cells
were stereotactically implanted into the right striatum of the
mice. Mice were sacrificed by CO2 inhalation and death was
confirmed by cervical dislocation if they exhibited excessive
weight loss of 20% body weight, tumor metastasis, lethargy,
or other signs of distress consisted with IACUC standards.
The number of survived nude mice was recorded and survival
analysis was performed using Kaplan Meier survival curve.
When the tumors grew to about 80 mm3, the tumor-bearing
mice were divided into four groups: (1) Control group, treated
with 0.9% sodium chloride; (2) EMAP-II group, treated with
80 ng/kg EMAP-II; (3) miR-20a (−) group, treated with miR-20a
(−) stable expressing cells; and (4) EMAP-II + miR-20a (−)
group, treated with miR-20a (−) stable expressing cells and
80 ng/kg EMAP-II.
Statistical Analysis
Data were presented as the mean ± standard deviation (SD)
and conducted with SPSS 13.0 (SPSS, IL, USA). Statistical
analysis was performed using student’s t-test and the one-
way ANOVA. P < 0.05 was considered to be statistically
significant.
RESULTS
Low-Dose EMAP-II Inhibited the Viability,
Migration and Invasion Ability of U-87 and
U-251 Cells
The effects of EMAP-II on the viability, migration and invasion
ability of U-87 and U-251 cells were evaluated by MTT and
transwell assay, respectively. As shown in Figures 1A,B, the cell
viability of U-87 and U-251 cells was inhibited by EMAP-II in
a time-dependent manner. The inhibition effect on cell viability
was most significant after cells were treated with EMAP-II for
0.5 h as compared to respective control group (P < 0.01).
Meanwhile, compared with the control group, the migration
and invasion ability of U-87 and U-251 cells were significantly
decreased after EMAP -II treatment for 0.5 h and 1 h (P < 0.05,
Figures 1E–J).
As shown in Figures 1C,D, there was no obvious difference
among 3-MA, Z-VAD and 3-MA + Z-VAD groups compared
with control group (P > 0.05), while EMAP-II significantly
inhibited the cell viability (P < 0.01). 3-MA pretreatment
significantly blocked EMAP-II’ effect on inhibiting the cell
viability, and recovered the cell viability to the level in control
group. The cell viability of EMAP-II + Z-VAD group was
significantly decreased compared with Z-VAD group (P < 0.01),
while there was no difference between EMAP-II + Z-VAD group
and EMAP-II group (P > 0.05). These results suggested that
Z-VAD had no impact on the inhibition effect of EMAP-II on
the cell viability. There were no significant differences between
EMAP-II + 3-MA + Z-VAD group and 3-MA + Z-VAD group
or EMAP-II + 3-MA group. But the cell viability was significantly
increased in EMAP-II + 3-MA + Z-VAD group compared
with EMAP-II and EMAP-II + Z-VAD group. These evidences
suggested that 3-MA could block the effect of EMAP-II on
inhibiting the cell viability of U-87 and U-251 gioma cells, while
Z-VAD had no such effect.
The Effects of Low-Dose EMAP-II on the
Protein Expression of LC3, P62/SQSTM1,
ATG7 and ATG5 in U-87 and U-251 Cells
Western blot assay was used to detect the protein expression of
LC3, P62/SQSTM1, ATG7 and ATG5 of U-87 and U-251 cells
after treatment with EMAP-II for 0.5, 1, 3 and 6 h. As shown in
Figures 2A–D, the conversion of LC3-I to LC3-II in U-87 and
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FIGURE 1 | Effects of endothelial-monocyte-activating polypeptide-II (EMAP-II) on proliferation, migration and invasion in U-87 and U-251 glioma
cells. (A) Effect of EMAP-II on growth inhibition in U-87 glioma cells. (B) Effect of EMAP-II on growth inhibition in U-251 glioma cells. (C)Effect of EMAP-II on growth
inhibition in U-87glioma cells combined with 3-Methyladenine (3-MA) or Z-VAD. (D) Effect of EMAP-II on growth inhibition in U-251glioma cells combined with 3-MA
or Z-VAD. (E–G) Quantification of cell migration and invasion of U-87 cells after treated with EMAP-II. (H–J) Quantification of cell migration and invasion of U-251
cells after treated with EMAP-II. Data is given as mean ± standard deviation (SD) of n = 8, ∗P < 0.05, ∗∗P < 0.01 vs. control group; ##P < 0.01 vs. Z-VAD group;
NNP < 0.01 vs. EMAP-II + Z-VAD group. Scale bars represent 40 µm.
U-251 cells increased at 0.5 h and 1 h compared with control
group (P < 0.05), and peaked at 0.5 h (P < 0.01); However, there
was no significant difference among 3 h, 6 h group and control
group. The expression of P62/SQSTM1, an autophagy substrate,
was significantly reduced in EMAP-II 0.5 h and 1 h groups
compared with the control group (P < 0.05, Figures 2E–H) and
the decline was most obvious at 0.5 h (P < 0.05). As shown
in Figures 2I–P, the protein expression levels of ATG7 and
ATG5 were significantly increased after EMAP-II treatment for
0.5 and 1 h, which was similar to LC3-II (P < 0.05). EMAP-II
induced the autophagy of human U-87 and U-251 glioma cells,
which might be correlated with the up-regulation of ATG7 and
ATG5.
The Effects of Low-Dose EMAP-II on the
miR-20a Expression Levels in U-87 and
U-251 Cells
The expression levels of miR-20a in U-87 and U-251 cells after
treating with EMAP-II were detected by quantitative real-time
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FIGURE 2 | Effects of EMAP-II on the expression of LC3, p62/SQSTM1, ATG7 and ATG5 in U-87 and U-251 glioma cells. (A,B,E,F,I,J,M,N) Western blot
analysis of the expressing levels of LC3, p62/SQSTM1, ATG7 and ATG5 in human U-87 glioma cells and U-251 glioma cells after treatment with EMAP-II for 0.5, 1, 3
and 6 h. (C,D,G,H,K,L,O,P) Western blot analysis of the LC3-II/-I, p62/SQSTM1/GAPDH, ATG7/GAPDH and ATG5/GAPDH levels in U-87 and U-251 glioma cells.
Data is given as mean ± SD of n = 8. ∗P < 0.05, ∗∗P < 0.01 vs. control group.
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FIGURE 3 | Effects of EMAP-II on the expression of microRNA-20a (miR-20a) in U-87 and U-251 glioma Cells. (A,B) The relative expression of miR-20a
was detected by real-time quantitative PCR in U-87 and U-251 glioma cells after treatment with EMAP-II for 0.5, 1, 3 and 6 h. Data is given as mean ± SD of n = 8.
∗P < 0.05, ∗∗P < 0.01 vs. control group.
PCR. As shown in Figures 3A,B, compared with control group,
EMAP-II significantly reduced the expression levels of miR-20a
normalized to U6 at 0.5 h and 1 h and the decline was most
obvious at 0.5 h (P < 0.05); meanwhile, there was no significant
difference among EMAP-II 3 h, 6 h groups and control group
(P > 0.05).
The Effects of miR-20a on the Protein
Expression of LC3 and P62/SQSTM1 in
U-87 and U-251 Cells
To further confirm whether miR-20a is involved in EMAP-II-
induced autophagy, western blot and immunofluorescence assays
were used to test the protein expression of LC3 and P62/SQSTM1
in U-87 and U-251 cells, which were transfected with a mimic or
inhibitor of miR-20a. As shown in Figures 4A–H, the protein
expression level of LC3-II/I significantly down-regulated and
the protein expression level of P62/SQSTM1 significantly up-
regulated in miR-20a (+) group compared with control and
miR-20a (+) NC groups (P < 0.05). Whereas, miR-20a (−)
group showed the opposite effect. The protein expression level
of LC3-II/I significantly up-regulated and the protein expression
level of P62/SQSTM1 significantly down-regulated in miR-20a
(−) group when compared to control and miR-20a (−) NC
groups. Compared with control group, EMAP-II significantly
up-regulated LC3-II/I protein expression and down-regulated
P62/SQSTM1 protein expression (P < 0.05). There was no
significant difference among EMAP-II, EMAP-II + miR-20a
(+) NC and EMAP-II + miR-20a (−) NC groups. Compared
with EMAP-II + miR-20a (+) NC group, EMAP-II + miR-20a
(+) significantly down-regulated LC3-II/I protein expression
and up-regulated P62/SQSTM1 protein expression (P < 0.05),
whereas EMAP-II + miR-20a (−) group showed no significant
differences.
Immunofluorescence staining was used to detect the
distribution and expression of LC3 and P62/SQSTM1 in U-87
and U-251 cells. As shown in Figure 4I, the LC3 expression
significantly increased in EMAP-II, miR-20a (−) and EMAP-II
+ miR-20a (−) groups, while decreased in miR-20a (+) group
and there was no significant change in EMAP-II + miR-20a (+)
group when compared to respective control group. Compared
with EMAP-II group, the expression of LC3 decreased in
EMAP-II + miR-20a (+) group and there was no significant
difference in EMAP-II + miR-20a (−) group. In addition, there
was a significant overlap between LC3 and lysosomal signals.
The expression change of P62/SQSTM1 was reversed to LC3,
which was decreased in EMAP-II, miR-20a (−) and EMAP-II
+ miR-20a (−) groups, while increased in miR-20a (+) group
and there was no significant difference between EMAP-II +
miR-20a (+) group and respective control groups. Compared
with EMAP-II group, the expression of P62/SQSTM1 increased
in EMAP-II + miR-20a (+) group and there was no significant
difference in EMAP-II + miR-20a (−) group. These results
indicated that miR-20a overexpression reversed the effect of
EMAP-II up-regulating the expression of LC3-II/I and down-
regulating the expression of p62/SQSTM1, and miR-20a might
be involved in the regulating of EMAP-II inducing autophagy.
MiR-20a Negatively Regulated ATG7 and
ATG5 Protein Expression Levels in U-87
and U-251 Cells
U-87 and U-251 cells were transfected with miR-20a mimics
and its inhibitors, and then the mRNA and protein levels of
ATG7 and ATG5 in U-87 and U-251 cells were detected by using
western blot and quantitative real-time PCR, respectively. As
shown in Figures 5A,B,G,H, there were no obvious differences
of ATG7 mRNA and ATG5 mRNA levels between miR-20a (+)
and miR-20a (+) NC groups, miR-20a (−) and miR-20a (−)
NC groups (P > 0.05). As shown in Figures 5C–F,I–L, there
were no obvious differences among control, miR-20a (+) NC and
miR-20a (−) NC groups. The protein expression levels of ATG7
and ATG5 in miR-20a (+) group were significantly decreased
compared with those of control group and miR-20a (+) NC
group (P < 0.05). However, protein expression levels of ATG7
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FIGURE 4 | The effects of miR-20a on protein expression levels of LC3 and P62/SQSTM1 in EMAP-II treated U-87 and U-251 glioma cells. (A,B,E,F)
Western blot analysis of the LC3-II/I and p62/SQSTM1 levels in human U-87 and U-251 glioma cells. (C,D,G,H) Western blot analysis of the LC3-II/I and
P62/SQSTM1/GAPDH levels in U-87 and U-251 glioma cells. (I)The distribution and expression of LC3 and P62/SQSTM1 in U-87 and U-251 glioma cells was
analyzed by immunofluorescence assay. Values are means ± SD (n = 8). ∗P < 0.05, ∗∗P < 0.01 vs. control group; #P < 0.05 vs. miR-20a (+) NC group; NP < 0.05
vs. miR-20a (−) NC group; ∆P < 0.05 vs. EMAP-II + miR-20a (+) NC group. Scale bar = 20 µm.
and ATG5 in miR-20a (−) group increased in comparison with
those of control group and miR-20a (−) NC group (P < 0.05).
MiR-20a Directly Targeted the 3′-UTR of
ATG7 and ATG5
As shown in Figures 6A,B, by using TargetScan Human Release
6.2 Software1, 3′-UTR of ATG7 and ATG5 was predicted as a
1http://www.targetscan.org
putative binding site matching with the seed region of miR-20a.
To verify that ATG7 or ATG5 3′-UTR is a direct target of
miR-20a, we cloned the reporter plasmid containing the wild
3′-UTR of ATG7 and ATG5 (atg7/ATG5-3UTR-Wt) andmutant
3′-UTR of ATG7 and ATG5 (atg7/ATG5-3UTR-mut). As shown
in Figure 6C, compared with ATG7 wt + miR-20a (+) NC
group, luciferase activity significantly decreased in ATG7wt +
miR-20a (+) group (P < 0.01), while ATG7 mut + miR-20a (+)
group showed no significant difference of luciferase activities
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FIGURE 5 | ATG7 and ATG5 was changed after overexpression or silencing of miR-20ain U-87 and U-251 glioma Cells. (A,B,G,H) The relative expression
of ATG7 mRNA and ATG5 mRNA levels were detected by real-time quantitative PCR in U-87 and U-251 glioma cells after overexpression or silencing of miR-20a.
(C,D,I,J) Western blot analysis of the ATG7 and ATG5 levels in human U-87 and U-251 glioma cells after overexpression or silencing of miR-20a. (E,F,K,L) Western
blot analysis of the ATG7/GAPDH and ATG5/GAPDH levels in U-87 and U-251 glioma cells. Data is given as mean ± SD of n = 8. ∗P < 0.05 vs. control group;
#P < 0.05 vs. miR-20a (+) NC group; NP < 0.05 vs. miR-20a (−) NC group.
with ATG7 mut + miR-20a (+) NC group (P > 0.05). Similarly,
luciferase activity significantly decreased in ATG5 wt + miR-20a
(+) group compared with ATG5 wt + miR-20a (+) NC group
(P < 0.05), while ATG5 mut + miR-20a (+) group showed
no significant differences of luciferase activities as compared to
ATG5 mut + miR-20a (+) NC group (P > 0.05, Figure 6D).
These results showed that miR-20a directly targeted the 3′-UTR
of ATG7 and ATG5.
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FIGURE 6 | ATG7 and ATG5 are the direct targets of miR-20a. (A,B) The putative binding sites of ATG7 3′UTR and ATG5 3′UTR matching with the seed region
of miR-20a were predicted with the help of TargetScan. (C,D) Relative luciferase activity was expressed as firefly/renilla luciferase activity. Values are means ± SD
(n = 4, each). ∗P < 0.05, ∗∗P < 0.01 vs. control group; #P < 0.05 vs. ATG5wt + miR-20a (+) NC group, ##P < 0.01 vs. ATG7 wt + miR-20a (+) group.
The Single or Combined Application of
EMAP-II and miR-20a Inhibitors on the
Viability, Migration and Invasion of U-87
and U-251 Cells
The functional role of EMAP-II and miR-20a inhibitor alone or
in combination on cell viability, migration and invasion of U-87
and U-251 cells was determined. As shown in Figures 7A,B,
compared with control group, the cell viability was decreased
in EMAP-II, miR-20a (−) and EMAP-II + miR-20a (−)
groups (P < 0.05). The combination of EMAP-II and miR-20a
(−) displayed greater inhibitory effect than either EMAP-II
or miR-20a (−) alone (P < 0.05). Similar to the above
results, EMAP-II and miR-20a (−) groups inhibited the
migration and invasion of cells, and the combination of
EMAP-II andmiR-20a (−) group displayedmaximum inhibitory
effect on the migration and invasion of cells (P < 0.05,
Figures 7C–H).
EMAP-II and miR-20a Inhibitor Inhibited
Tumor Growth In Vivo
The growth-inhibitory effect of EMAP-II and miR-20a inhibitor
on U-87 and U-251 cells was further tested in xenografted mice.
As shown in Figures 8A–F, tumor volumes of xenografts were
significantly suppressed in EMAP-II, miR-20a (−) and EMAP-II
+ miR-20a (−) groups as compared to control group (P < 0.01),
and the tumor volumes was most significantly decreased in
EMAP-II + miR-20a (−) group (P < 0.01). Survival curve
analysis showed that, survival time of nude mice was longer in
EMAP-II, miR-20a (−) and EMAP-II +miR-20a (−) groups than
that in control group, and was significantly longest in EMAP-II
+ miR-20a (−) group (Figures 8G,H). These data showed that
nude mice were treated by EMAP-II combined with miR-20a
inhibitor produced the smallest tumors and had the highest
survival rate.
DISCUSSION
The present study showed that low doses of EMAP-II
(0.05 nM) effectively inhibited the viability, migration, and
invasion of human U-87 and U-251 glioma cells. This was
reversed by the autophagy inhibitor 3-MA, while the apoptosis
inhibitor Z-VAD had no effect. EMAP-II up-regulated the
expression of the proteins LC3-II/I, ATG7 and ATG5, but
down-regulated P62/SQSTM1 expression in the U-87 and
U-251 glioma cells, demonstrating that the antitumor activity
results from the induction of autophagy, not apoptosis. The
expression levels of miR-20a decreased significantly after
EMAP-II treatment. The EMAP-II-induced up-regulation of
LC3-II/I, and down-regulation of P62/SQSTM1, was blocked by
miR-20a overexpression; while miR-20a had a negative effect
on ATG7 and ATG5 protein expression. The dual-luciferase
reporter assay revealed that miR-20a binds to the 3′UTR of ATG7
and ATG5 mRNA. Results above demonstrated that EMAP-II
up-regulates expression of ATG7 and ATG5 through miR-20a
inhibition. This induced autophagy of the glioma cells. EMAP-
II and miR-20a inhibition significantly reduced the viability,
migration and invasion of U-87 and U-251 cells in a synergistic
manner. Furthermore, nude mice carrying silencing-expressed
miR-20a combined with EMAP-II treatment had the smallest
tumors and highest survival.
EMAP-II is a potential anti-tumor substance with dual
effects: opening the BTB and inhibiting tumor growth.
This group has investigated the molecular mechanism
of opening the BTB, but the anti-tumor effect is poorly
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FIGURE 7 | EMAP-II alone and EMAP-II combined with miR-20a inhibitor inhibited the proliferation, migration and invasion of U-87 and U-251 Cells.
(A,B) The effects of EMAP-II and miR-20a inhibitor on growth inhibition and the migration of U-87 and U-251 cells were assessed by MTT. (C–E) Quantification of
cell migration and invasion of U-87 cells. (F–H) Quantification of cell migration and invasion of U-251 cells. Data is given as mean ± SD of n = 8. ∗P < 0.05,
∗∗P < 0.01 vs. control group; #P < 0.05 vs. miR-20a (−) NC; NNP < 0.01 vs. NS + miR-20a (−) NC group; 4P < 0.05 vs. EMAP-II group; >P < 0.05, >>P < 0.01
vs. miR-20a (−) group. Scale bars represent 40 µm.
understood. As a pro-inflammatory cytokine, EMAP-II triggers
apoptosis of endothelial cells and inhibits tumor angiogenesis
(Berger et al., 2000). EMAP-II decreases the viability of
pancreatic ductal adenocarcinoma cells through inhibition
of fibronectin-dependent proliferation (Schwarz et al., 2010);
low-dose (0.05 nM) EMAP-II also induces the apoptosis of C6
glioma cells via the mitochondrial pathway (Liu et al., 2015b).
In addition, EMAP-II activates the autophagy pathway and
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FIGURE 8 | EMAP-II and miR-20a inhibitor inhibited tumor growth in vivo. (A–D) Represent active images of mice and tumors removed from the xenografted
mice. (E,F) Tumor growth curves in nude mice. Tumor volume was calculated every 5 days after injection (n = 5). (G,H) The survival curves of nude mice injected
(n = 10). ∗∗P < 0.01 vs. control group; #P < 0.05 vs. EMAP-II group; NP < 0.05 vs. miR-20a (−) group.
decreases the viability of U-118 glioma cells (Liu et al., 2013).
Thus, EMAP-II can exert anti-tumor effects through a variety
of pathways. This study found that low doses of EMAP-II
significantly inhibit the viability, migration and invasion of U-87
and U-251 glioma cells by inhibiting biological activity.
Increasing evidence shows that programmed cell death is
important for inducing tumor cell death, primarily by apoptosis
or autophagy. Drug-induced autophagic cell death is an effective
cancer treatment. For example, fluorouracil up-regulated
expression of the protein Beclin-1 triggers autophagic cell death
of gastric cancer cells (Yang and Pan, 2015). Dihydroartemisinin
increased Beclin-1 and LC3-B expression levels, induced
autophagy in glioma cells, inhibited cell viability, and enhanced
the anti-tumor effect of temozolomide (Zhang et al., 2015).
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The autophagy inhibitor 3-MA and caspase inhibitor Z-VAD
were applied to determine whether low-dose EMAP-II inhibits
the biological activity of human U-87 and U-251 glioma
cells through autophagy or apoptosis. Results showed that
3-MA can block EMAP-II-induced inhibition of U-87 and
U-251 cell viability, while Z-VAD had no impact. The above
findings indicated that low-dose EMAP-II reduced viability
of tumor cells through autophagy, and was not associated
with apoptosis. A previous study has reported that low doses
of EMAP-II inhibited the viability of rat C6 glioma cells via
apoptosis, in contrast to these findings showing the autophagy-
based contribution of low-dose EMAP-II on U-87 and U-251
cells, but no evidence of apoptosis. The discrepancy could be
explained by the different cell sources and strains that were used.
LC3 is a protein involved in the formation of the
autophagosome. Synthetic LC3 is cut by ATG4 to make
LC3-I, which binds the autophagic membrane with the help of
ATG3 and ATG7, when it then transforms into active LC3-II.
Therefore, the conversion ratio of LC3-I to LC3-II represents
autophagy activity (Tanida et al., 2004). The results of this study
found that EMAP-II significantly increased LC3-II/I expression
in U-87 and U-251 glioma cells with a peak at 0.5 h, indicating
that EMAP-II can induce cell autophagy. P62/SQSTM1 is
degraded during autophagy, reflecting autolysosomal activity
and autophagic flux (Ichimura and Komatsu, 2010). It was
also shown that P62/SQSTM1, which is eliminated through
autophagy, inhibits tumor growth (Moscat and Diaz-Meco,
2009). In this study, we found that EMAP-II significantly
lowered P62/SQSTM1 expression, and the decline was most
obvious at 0.5 h. This demonstrated that low-dose EMAP-II
inhibits the viability of U-87 and U-251 glioma cells via
autophagy.
To investigate the potential mechanism underlying EMAP-II-
induced autophagy in U-87 and U-251 glioma cells, the effects
of EMAP-II on the expression of ATG7 and ATG5 were
studied. EMAP-II significantly increased ATG5 and ATG7
expression in U-87 and U-251 cells with a peak at 0.5 h. It is
possible that EMAP-II induced autophagy of U-87 and U-251
cells by up-regulation of ATG7 and ATG5 expression. ATG7
serves as an E1-activating enzyme involved in autophagosome
formation and vesicle progression (Weidberg et al., 2011).
ATG7 knockout mice die within 1 day of birth and show
reduced pup size, due to the impaired autophagy pathway
(Tanzer and Stadler, 2004). ATG5 plays a crucial role in
autophagosome elongation and apoptosis; even it is associated
with the occurrence of tumors in various tissues (Liu et al.,
2015a). These data indicate that EMAP-II induced autophagy
of U-87 and U-251 cells by up-regulating ATG7 and ATG5
expression.
MiR-20a acts as a tumor promoter or suppressor, depending
on the cell type. For example, miR-20a overexpression
significantly inhibited the proliferation and invasive capacity
of thyroid cancer cells (Xiong et al., 2014), while it is a cancer-
promoter in cervical cells (Kang et al., 2012). MiR-20a expression
significantly increased in glioma stem cells, which enhanced
invasiveness (Wang et al., 2015); the degree of malignancy in
brainstem gliomas was often higher in children than in adults,
which correlated with up-regulation of miR-20a in pediatric
brainstem gliomas (Wang et al., 2012). This indicates that
miR-20a may serve as a cancer-promoting gene and affect the
biological activity of glioma cells. Our study found that the
expression level of miR-20a was significantly decreased in U-87
and U-251 glioma cells after EMAP-II treatment, suggesting
EMAP-II inhibited the viability, migration, and invasion of
glioma cells by decreasing miR-20a via an unknown mechanism.
It has been reported that miR-20a can affecte autophagy
in C2C12 cells (Wu et al., 2012). However, whether EMAP-II
induced autophagy of U-87 and U-251 cells via regulation of
miR-20a is not clear. In this study, miR-20a overexpression
prevented the EMAP-II-induced increase of LC3-II/I and
decreases of P62/SQSTM1 expression. Research showed that
miR-20a overexpression inhibits transformation from LC3-I to
LC3-II, thereby negatively regulating autophagy in liver cancer
cells (Chen et al., 2015). These results support the findings in this
study. Therefore, EMAP-II can inhibit miR-20a expression and
induce autophagy of U-87 andU-251 glioma cells by an unknown
mechanism.
MiR-20a targets the ATG ULK1 post-transcriptionally and
regulates autophagy of C2C12 cells (Wu et al., 2012), suggesting
control by regulating expression of the autophagy-related
protein. The results of this study showed that EMAP-II treatment
of U-87 and U-251 cells led to a significant decrease in miR-20a
expression and a significant increase in ATG7 and ATG5
expression. This suggests that EMAP-II up-regulation of ATG7
and ATG5 by down-regulation of miR-20a leads to autophagy.
Using the bioinformatics Software TargetScan Human Release
6.2, putative binding sites for miR-20a were predicted on ATG7
and ATG5. The dual-luciferase reporter assay illustrated that
miR-20a binds with the 3′-UTR of ATG7 and ATG5 mRNA,
respectively. In addition, miR-20a overexpression significantly
down-regulated ATG7 and ATG5 protein levels. However,
neither miR-20a overexpression nor silencing affected mRNA
expression. This suggests that miR-20a post-transcriptionally
regulates ATG7 andATG5. Therefore, EMAP-IImay up-regulate
expression of ATG5 and ATG7 via down-regulation of miR-20a,
inducing autophagy in glioma cells.
The tumor-promoting effect of miR-20a has been reported
in glioma cells and tissues (Yao et al., 2012). This study
finds that EMAP-II and miR-20a inhibition have an antitumor
effect toward glioma cells. Results showed that both EMAP-II
and the miR-20a inhibitor effectively reduced cell viability,
migration and invasion, and the combination brought synergistic
or enhanced effects. A subsequent study analyzed the effect
of EMAP-II and the miR-20a inhibitor on tumor size and
survival time in a nude mouse model of subcutaneous xenograft.
EMAP-II and the miR-20a inhibitor contributed to reduced
tumor size and prolonged survival of the mice, highlighting the
synergistic effect against glioma.
In summary, this is the first study proposing that low-
dose EMAP-II treatment induces autophagy of U-87 and U-251
glioma cells leading to inhibition of cell viability, migration and
invasion via the down-regulation of miR-20a. The mechanism of
action is associated with negative regulation of the autophagy-
related proteins ATG7 and ATG5 by miR-20a. Furthermore,
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combination of EMAP-II with a miR-20a inhibitor significantly
reduces the proliferation, migration and invasion of glioma cells,
prevents tumor growth in vivo, and exerts a synergistic effect
against glioma. Therefore, EMAP-II combined with a miR-20a
inhibitor shows promise as a new treatment for glioma.
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